Elizabeth Nally, Medical Oncology SpR at Barts Health, shared Cristiane Bergerot’s post on X, adding:
“Totally agree!
Fantastic to see this impressive international investigator-led effort coming together ESMO26 With 5 UK sites now open, we’re excited to contribute to answering one of the key outstanding questions in first-line RCC.”
Cristiane Bergerot, Former Postdoc Fellow and Research Consultant at City of Hope, shared:
“Exciting to see early findings from CARE1 presented at ESMO26!
A landmark international phase III trial aiming to optimize first-line treatment selection in metastatic RCC Proud to be part of this important collaboration, led by the outstanding.”
You can also read:
LITESPARK-011 at ESMO 2026: Association Between HRQoL and Clinical Outcomes in Advanced RCC
